Merck Announces Presentation of Results from Two Phase 2 Studies of Investigational Triple-Combination Chronic Hepatitis C Therapy at The Liver Meeting®
Dateline City:
KENILWORTH, N.J.
Merck Advances to Part B of C-CREST Phase 2 Clinical Development Program
KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada,
today announced the presentation of results from the initial phase (Part
A) of the company’s C-CREST 1 and 2 Phase 2
clinical development program evaluating two investigational all-oral,
triple-combination treatment regimens – a regimen of grazoprevir1,
MK-36822 and elbasvir3; and a regimen
of grazoprevir, MK-3682 and MK-84084 – in treatment-naïve
patients with chronic hepatitis C virus (HCV) genotypes (GT) 1, 2 or 3
infection.
Language:
English
Contact:
MerckMedia:Doris Li, 908-246-5701Sarra Herzog, 201-669-6570orInvestors:Teri Loxam, 908-740-1986Amy Klug, 908-740-1898
Ticker Slug:
Ticker: MRK Exchange: NYSE
read more
Source: Merck.com - Research and Development News - Category: Pharmaceuticals Tags: Research and Development News Corporate News Latest News #Merck #MRK $MRK Hep C Hepatitis C MSD The Liver Meeting Source Type: news